Abstract
New SARS-CoV-2 variants with mutations in the spike glycoprotein have arisen independently at multiple locations and may have functional significance. The combination of mutations in the 501Y.V2 variant first detected in South Africa include the N501Y, K417N, and E484K mutations in the receptor binding domain (RBD) as well as mutations in the N-terminal domain (NTD). Here we address whether the 501Y.V2 variant could escape the neutralizing antibody response elicited by natural infection with earlier variants. We were the first to outgrow two variants of 501Y.V2 from South Africa, designated 501Y.V2.HV001 and 501Y.V2.HVdF002. We examined the neutralizing effect of convalescent plasma collected from six adults hospitalized with COVID-19 using a microneutralization assay with live (authentic) virus. Whole genome sequencing of the infecting virus of the plasma donors confirmed the absence of the spike mutations which characterize 501Y.V2. We infected with 501Y.V2.HV001 and 501Y.V2.HVdF002 and compared plasma neutralization to first wave virus which contained the D614G mutation but no RBD or NTD mutations. We observed that neutralization of the 501Y.V2 variants was strongly attenuated, with IC50 6 to 200-fold higher relative to first wave virus. The degree of attenuation varied between participants and included a knockout of neutralization activity. This observation indicates that 501Y.V2 may escape the neutralizing antibody response elicited by prior natural infection. It raises a concern of potential reduced protection against re-infection and by vaccines designed to target the spike protein of earlier SARS-CoV-2 variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Bill and Melinda Gates Investment INV-018944 (AS) and by the South African Medical Research Council and the Department of Science and Innovation (TdO).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Nasopharyngeal/oropharyngeal swab samples and plasma samples were obtained from six hospitalized adults with PCR-confirmed SARS-CoV-2 infection enrolled in a prospective cohort study ap- proved by the Biomedical Research Ethics Committee (BREC) at the University of KwaZulu-Natal (reference BREC/00001275/2020). The 501Y.V2 variants were obtained from residual nasopharyngeal/oropharyngeal samples used for routine SARS-CoV-2 diagnostic testing by the National Health Laboratory Service, through our SARS-CoV-2 genomic surveillance program (BREC approval reference BREC/00001510/2020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵§ Network for Genomic Surveillance in South Africa (NGS-SA)
Shareef Abrahams1, Luiz Carlos Junior Alcantara2, Arghavan Alisoltani-Dehkordi3,4, Mushal Allam5, Jinal N Bhiman5,6, Mary-Ann Davies7,8, Deelan Doolabh9, Susan Engelbrecht10, Vagner Fonseca11, Marta Giovanetti2, Allison J Glass6,12, Adam Godzik4, Dominique Goedhals13, Diana Hardie14, Marvin Hsiao14, Arash Iranzadeh4, Arshad Ismail5, Stephen Korsman14, Sergei L Kosakovsky Pond15, Oluwakemi Laguda-Akingba1,16, Jose Lourenco17, Gert Marais14, Darren Martin9,18, Caroline Maslo19, Koleka Mlisana20,21, Thabo Mohale5, Nokukhanya Msomi22, Innocent Mudau9, Francesco Petruccione23,24, Wolfgang Preiser10, Emmanuel James San11, Bryan Trevor Sewell25, Lynn Tyers9, Gert Van Zyl10, Anne von Gottberg5,6, Sibongile Walaza5,26, Steven Weaver15, Constantinos Kurt Wibmer5, Carolyn Williamson9,14,21, Denis York27.
1National Health Laboratory Service, Port Elizabeth, South Africa. 2Laboratorio de Flavivirus, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil. 3Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa. 4Division of Biomedical Sciences, University of California Riverside School of Medicine, Riverside, California, USA. 5National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa. 6School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 7Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa. 8Western Cape Government: Health, Cape Town, South Africa. 9Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa. 10Division of Medical Virology at NHLS Tygerberg Hospital and Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 11KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Department of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa. 12Department of Molecular Pathology, Lancet Laboratories, Johannesburg, South Africa. 13Division of Virology at NHLS Universitas Academic Laboratories, University of The Free State, Bloemfontein, South Africa. 14Division of Medical Virology at NHLS Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa. 15Institute for Genomics and Evolutionary Medicine, Temple University, Philadelphia, Pennsylvania, USA. 16Department of Laboratory Medicine and Pathology, Faculty of Health Sciences, Walter Sisulu University, Mthatha, South Africa. 17Department of Zoology, University of Oxford, Oxford, United Kingdom. 18Computational Biology Division, Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa. 19Department of Quality Leadership, Netcare Hospitals, Johannesburg, South Africa. 20National Health Laboratory Service, Johannesburg, South Africa. 21Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa. 22Discipline of Virology, University of KwaZulu-Natal, School of Laboratory Medicine and Medical Sciences and National Health Laboratory Service, Durban, South Africa. 23Centre for Quantum Technology, University of KwaZulu-Natal, Durban, South Africa 24National Institute for Theoretical Physics (NITheP), KwaZulu-Natal, South Africa. 25Structural Biology Research Unit, Department of Integrative Biomedical Sciences, University of Cape Town, Rondebosch, South Africa. 26School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 27Molecular Diagnostics Services, Durban, South Africa.
↵§§ COMMIT-KZN Team
Moherndran Archary1, Kaylesh J. Dullabh2, Philip Goulder3,4, Guy Harling3,5, Rohen Harrichandparsad6, Kobus Herbst3,7, Prakash Jeena1, Thandeka Khoza3, Nigel Klein3,8, Henrik Kløverpris3,9,10, Alasdair Leslie3,9, Rajhmun Madansein2, Mohlopheni Marakalala3,9, Matilda Mazibuko3, Mosa Moshabela11, Ntombifuthi Mthabela3, Kogie Naidoo12, Zaza Ndhlovu3,13, Thumbi Ndung’u3,9,14,15, Kennedy Nyamande16, Nesri Padayatchi12, Vinod Patel17, Theresa Smit3, Adrie Steyn3,18, Emily Wong3,18.
1Department of Paediatrics and Child Health, University of KwaZulu-Natal, Durban, South Africa. 2Department of Cardiothoracic Surgery, University of KwaZulu-Natal, Durban, South Africa. 3Africa Health Research Institute, Durban, South Africa. 4Department of Paediatrics, Oxford, UK. 5Institute for Global Health, University College London, UK. 6Department of Neurosurgery, University of KwaZulu-Natal, Durban, South Africa. 7South African Population Research Infrastructure Network, Durban, South Africa. 8Institute of Child Health, University College London, UK. 9Division of Infection and Immunity, University College London, London, UK. 10Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. 11College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. 12Centre for the AIDS Programme of Research in South Africa, Durban, South Africa. 13Ragon Institute of MGH, MIT and Harvard, Boston, USA. 14HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. 15Max Planck Institute for Infection Biology, Berlin, Germany. 16Department of Pulmonology and Critical Care, University of KwaZulu-Natal, Durban, South Africa. 17Department of Neurology, University of KwaZulu-Natal, Durban, South Africa. 18Division of Infectious Diseases, University of Alabama at Birmingham.
Data Availability
All sequence data is available at GISAID.
